Sigrun Hallmeyer, MD
Hematology & Oncology · Park Ridge, ILNPI 1164481412
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 48.9% of the total. Reporting peaked in 2019 at $44,547 and has fallen 58.9% since, to $18,305 in 2025. Among hematology & oncology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 129 payments — averaging $914.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$58K
- AstraZeneca$21K
- Gilead$6K
- Stemline Therapeutics Inc.$5K
- Athenex Pharmaceutical Division, LLC$5K
- Immunocore Limited$5K
- plus $19K from 15 others
Across 237 payments — averaging $8061.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.3M
- E.r. Squibb & Sons, L.L.C.$147K
- Pfizer$116K
- Genentech, Inc.$70K
- Boehringer Ingelheim$69K
- Regeneron$65K
- plus $139K from 6 others
What the payments were for
- Consulting fees$50,27643%
- Speaking & faculty fees$58,34049%
- Grants$2500%
- Travel & lodging$6,7396%
- Food & beverage$2,1882%
- Education$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 52 | $57,684 |
| AstraZeneca | 25 | $20,589 |
| Gilead | 14 | $6,187 |
| Stemline Therapeutics Inc. | 2 | $4,960 |
| Athenex Pharmaceutical Division, LLC | 3 | $4,600 |
| Immunocore Limited | 2 | $4,500 |
| Novartis | 5 | $4,170 |
| Array Biopharma Inc | 2 | $3,060 |
| Pfizer | 4 | $2,743 |
| Daiichi Sankyo Inc. | 3 | $2,048 |
| Eli Lilly | 1 | $1,875 |
| Bristol Myers Squibb | 3 | $1,840 |
| Seagen Inc. | 1 | $1,375 |
| R-pharm US LLC | 3 | $1,370 |
| Endomagnetics Ltd | 1 | $218 |
| Merck | 3 | $215 |
| Merit Medical Systems Inc | 1 | $130 |
| Regeneron Healthcare Solutions, Inc. | 1 | $119 |
| Lilly USA, LLC | 1 | $106 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $101 |
| Genentech USA, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$117,911 in reported general payments places this provider in the 90th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 44 | $648,821 |
| EliquisApixaban | 27 | $27,895 |
| Anastrozole | 353 | $7,098 |
| Exemestane | 20 | $2,801 |
| Letrozole | 122 | $2,014 |
| Tamoxifen Citrate | 43 | $1,062 |
| SynthroidLevothyroxine Sodium | 14 | $404 |
| Levothyroxine Sodium | 27 | $314 |
| Dexamethasone | 13 | $280 |
| Entecavir | 19 | $280 |
| Alendronate Sodium | 37 | $279 |
| Prednisone | 39 | $172 |
| Prochlorperazine Maleate | 16 | $140 |
| Methylprednisolone | 16 | $63 |
| Ondansetron Hcl | 11 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $106 | $648,82144 claims |
| PfizerEliquis | $2,743 | $27,89527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Park Ridge
- Mohamad Khair KhasawnehMaywood$998K
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- John BerryBerwyn$687K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Tulio RodriguezZion$337K
- Chih-Yi LiaoChicago$317K
- Gary KayElk Grove Village$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.